226 related articles for article (PubMed ID: 22576130)
1. Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck JM; Batey MA; Zhao Y; Jenkins H; Richardson CJ; Cano C; Tavecchio M; Barbeau J; Bardos J; Cornell L; Griffin RJ; Menear K; Slade A; Thommes P; Martin NM; Newell DR; Smith GC; Curtin NJ
Mol Cancer Ther; 2012 Aug; 11(8):1789-98. PubMed ID: 22576130
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
3. KU-0060648 inhibits hepatocellular carcinoma cells through DNA-PKcs-dependent and DNA-PKcs-independent mechanisms.
Chen MB; Zhou ZT; Yang L; Wei MX; Tang M; Ruan TY; Xu JY; Zhou XZ; Chen G; Lu PH
Oncotarget; 2016 Mar; 7(13):17047-59. PubMed ID: 26933997
[TBL] [Abstract][Full Text] [Related]
4. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
Wise HC; Iyer GV; Moore K; Temkin SM; Gordon S; Aghajanian C; Grisham RN
Sci Rep; 2019 Dec; 9(1):18882. PubMed ID: 31827119
[TBL] [Abstract][Full Text] [Related]
5. Suppression of DNA-PKcs and Ku80 individually and in combination: Different effects of radiobiology in HeLa cells.
Zhuang L; Cao Y; Xiong H; Gao Q; Cao Z; Liu F; Qiu H; Yu S; Huang X
Int J Oncol; 2011 Aug; 39(2):443-51. PubMed ID: 21573502
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Batey MA; Zhao Y; Kyle S; Richardson C; Slade A; Martin NM; Lau A; Newell DR; Curtin NJ
Mol Cancer Ther; 2013 Jun; 12(6):959-67. PubMed ID: 23512991
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Kopa P; Macieja A; Gulbas I; Pastwa E; Poplawski T
Mol Biol Rep; 2020 Jan; 47(1):67-76. PubMed ID: 31583565
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks.
Dong J; Zhang T; Ren Y; Wang Z; Ling CC; He F; Li GC; Wang C; Wen B
Oncotarget; 2017 Apr; 8(14):22662-22673. PubMed ID: 28186989
[TBL] [Abstract][Full Text] [Related]
9. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
10. NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Hisatomi T; Sueoka-Aragane N; Sato A; Tomimasu R; Ide M; Kurimasa A; Okamoto K; Kimura S; Sueoka E
Blood; 2011 Mar; 117(13):3575-84. PubMed ID: 21245486
[TBL] [Abstract][Full Text] [Related]
11. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.
Amrein L; Loignon M; Goulet AC; Dunn M; Jean-Claude B; Aloyz R; Panasci L
J Pharmacol Exp Ther; 2007 Jun; 321(3):848-55. PubMed ID: 17351105
[TBL] [Abstract][Full Text] [Related]
12. Biochemical evidence for Ku-independent backup pathways of NHEJ.
Wang H; Perrault AR; Takeda Y; Qin W; Wang H; Iliakis G
Nucleic Acids Res; 2003 Sep; 31(18):5377-88. PubMed ID: 12954774
[TBL] [Abstract][Full Text] [Related]
13. The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown
Timme CR; Rath BH; O'Neill JW; Camphausen K; Tofilon PJ
Mol Cancer Ther; 2018 Jun; 17(6):1207-1216. PubMed ID: 29549168
[TBL] [Abstract][Full Text] [Related]
14. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.
Willmore E; de Caux S; Sunter NJ; Tilby MJ; Jackson GH; Austin CA; Durkacz BW
Blood; 2004 Jun; 103(12):4659-65. PubMed ID: 15010369
[TBL] [Abstract][Full Text] [Related]
15. Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.
Mould E; Berry P; Jamieson D; Hill C; Cano C; Tan N; Elliott S; Durkacz B; Newell D; Willmore E
Biochem Pharmacol; 2014 Mar; 88(1):58-65. PubMed ID: 24418411
[TBL] [Abstract][Full Text] [Related]
16. Suppression of DNA-dependent protein kinase sensitize cells to radiation without affecting DSB repair.
Gustafsson AS; Abramenkovs A; Stenerlöw B
Mutat Res; 2014 Nov; 769():1-10. PubMed ID: 25771720
[TBL] [Abstract][Full Text] [Related]
17. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
Pastwa E; Poplawski T; Lewandowska U; Somiari SB; Blasiak J; Somiari RI
Int J Biochem Cell Biol; 2014 Aug; 53():423-31. PubMed ID: 24953561
[TBL] [Abstract][Full Text] [Related]
18. Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionizing radiation.
Mitchell J; Smith GC; Curtin NJ
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1520-7. PubMed ID: 19931734
[TBL] [Abstract][Full Text] [Related]
19. The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention.
Peirce SK; Findley HW; Prince C; Dasgupta A; Cooper T; Durden DL
Cancer Chemother Pharmacol; 2011 Aug; 68(2):325-35. PubMed ID: 20972874
[TBL] [Abstract][Full Text] [Related]
20. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.
Deriano L; Guipaud O; Merle-Béral H; Binet JL; Ricoul M; Potocki-Veronese G; Favaudon V; Maciorowski Z; Muller C; Salles B; Sabatier L; Delic J
Blood; 2005 Jun; 105(12):4776-83. PubMed ID: 15718417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
